News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-114

no u got stuck in the stock because we all see the potential of the stock and we all want to ride the upside, it has taken a lot longer and a lot more dilution than we can stomach. from a dispassionate non holder perspective however, which other biotech with so much real potential in proven commercial space on ASX is capped at 20m, the continued expression of frustrations is self defeating.
If your intention is to "warn" other potential investors off the stock, you are already proven the point of cutting off your nose to spite your face.
The converse side of your argument is that if the company does come good and at this point, it has a more than even chance pulling it off, by warming them off, you have deprive potential investors of the upside. Mt suggestion is to let them do their own due diligence and if the risk appetite allows for an investment in AHZ, so be it.